EP3601266

Setnar indólín-afleiður sem hindrar fyrir eftirmyndun beinbrunasóttarveiru

  • Status:
    EP einkaleyfi í gildi á Íslandi
  • EP appl. date:
    29.3.2018
  • EP published:
    28.4.2021
  • EP application number:
    18715612.0
  • Max expiry date:
    28.3.2038
  • Expiry date:
    28.3.2024
  • Next due date:
    31.3.2024
  • Title:
    SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS

Timeline

Today
29.3.2018EP application
28.4.2021EP Publication
9.6.2021Translation submitted
15.7.2021Registration published
28.3.2024Expires

Owner

  • Name:
    Janssen Pharmaceuticals, Inc.
  • Address:
    1125 Trenton-Harbourton Road, Titusville, NJ 08560, US
  • Name:
    Katholieke Universiteit Leuven
  • Address:
    Waaistraat 6, bus 5105, 3000 Leuven, BE

Inventor

  • Name:
    KESTELEYN, Bart Rudolf Romanie
  • Address:
    2340 Beerse, BE
  • Name:
    BONFANTI, Jean-François
  • Address:
    92787 Issy-les-Moulineaux Cedex 9, FR
  • Name:
    COESEMANS, Erwin
  • Address:
    2340 Beerse, BE
  • Name:
    RABOISSON, Pierre Jean-Marie Bernard
  • Address:
    2340 Beerse, BE
  • Name:
    MARCHAND, Arnaud Didier M
  • Address:
    3001 Leuven (Heverlee), BE
  • Name:
    BARDIOT, Dorothée Alice Marie-Eve
  • Address:
    3001 Leuven (Heverlee), BE

Agent

  • Name:
    Árnason Faktor ehf.
  • Address:
    Guðríðarstíg 2-4, 113, Reykjavík,

Priority

  • Number:
    17164048
  • Date:
    31.3.2017
  • Country:
    EP

Classification

  • Categories:
    C07D 403/12, A61P 31/14, A61P 31/12, A61K 31/4196, A61K 45/06

Annual fees

Number

Paid

Expires

Payer

Number: 5

Paid: 8.2.2022

Expires: 28.3.2023

Payer: Árnason Faktor ehf.

Number: 6

Paid: 8.2.2023

Expires: 28.3.2024

Payer: Árnason Faktor ehf.

Upload documents